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Association of PHB 1630 C4T and MTHFR 677 C4T
polymorphisms with breast and ovarian cancer risk in BRCA1/2
mutation carriers: results from a multicenter study
BACKGROUND: The variable penetrance of breast cancer in BRCA1/2 mutation carriers suggests that other genetic or environmental
factors modify breast cancer risk. Two genes of special interest are prohibitin (PHB) and methylene-tetrahydrofolate reductase
(MTHFR), both of which are important either directly or indirectly in maintaining genomic integrity.
METHODS: To evaluate the potential role of genetic variants within PHB and MTHFR in breast and ovarian cancer risk, 4102 BRCA1 and
2093 BRCA2 mutation carriers, and 6211 BRCA1 and 2902 BRCA2 carriers from the Consortium of Investigators of Modifiers of
BRCA1 and BRCA2 (CIMBA) were genotyped for the PHB 1630 C4T (rs6917) polymorphism and the MTHFR 677 C4T
(rs1801133) polymorphism, respectively.
RESULTS: There was no evidence of association between the PHB 1630 C4T and MTHFR 677 C4T polymorphisms with either
disease for BRCA1 or BRCA2 mutation carriers when breast and ovarian cancer associations were evaluated separately. Analysis that
evaluated associations for breast and ovarian cancer simultaneously showed some evidence that BRCA1 mutation carriers who had
the rare homozygote genotype (TT) of the PHB 1630 C4T polymorphism were at increased risk of both breast and ovarian cancer
(HR 1.50, 95%CI 1.10–2.04 and HR 2.16, 95%CI 1.24–3.76, respectively). However, there was no evidence of association under a
multiplicative model for the effect of each minor allele.
CONCLUSION: The PHB 1630TT genotype may modify breast and ovarian cancer risks in BRCA1 mutation carriers. This association
need to be evaluated in larger series of BRCA1 mutation carriers.
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Breast and ovarian cancers are among the most common
malignancies diagnosed in women. The major inherited suscept-
ibilities to breast and/or ovarian cancer are germline mutations in
either BRCA1 or BRCA2. Even though both BRCA1 and
BRCA2 confer a high risk of disease, it is not identical for all
mutation carriers, which suggests there are other genetic and
environmental factors that are capable of modifying disease
penetrance. The identification of additional genetic factors that
could modify disease expression in BRCA1 or BRCA2 mutation
carriers is an important facet to improving risk assessment.
Two genes of special interest are prohibitin (PHB) and methylene-
tetrahydrofolate reductase (MTHFR), both of which are important
either directly or indirectly in maintaining genomic integrity,
including cell cycle control, DNA synthesis and methy-
lation (Roskams et al, 1993; Bagley and Selhub, 1998; Friso et al,
2002).
PHB and MTHFR polymorphisms and cancer risk in BRCA1/2 carriers
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The PHB gene is located on human chromosome 17q21,
a region that undergoes frequent loss of heterozygosity in familial
and sporadic breast and ovarian cancers (White et al, 1991;
Black et al, 1993; Nagai et al, 1994). The gene product is a 30-kD
intracellular antiproliferative protein, which interacts with the
retinoblastoma tumour suppressor protein to regulate E2F-
mediated transcription (White et al, 1991; Wang et al, 1999).
The 30 untranslated region (30UTR) of the PHB gene encodes a
tumour suppressive trans-acting regulatory RNA molecule that
arrests cell proliferation between the G1 and S phases of the
cell cycle in normal epithelial cells and tumour breast cell lines
(Jupe et al, 1996a; Manjeshwar et al, 2003). A single-nucleotide
polymorphism (SNP), a C-to-T transition at position 1630 in the
3´UTR (rs6917) creates a variant, which lacks antiproliferative
activity (Jupe et al, 1996b) and significantly reduces cell motility
(Manjeshwar et al, 2004). The presence of the T allele was shown to
cause inactivation of the bioactive rRNA resulting in the loss of its
proapoptotic function and a subsequent risk of malignant growth
(Manjeshwar et al, 2003), and was reported to be associated with
significantly increased risk of breast cancer in women aged less
than 50 years who had a first-degree relative with breast cancer
(Jupe et al, 2001).
The MTHFR gene produces a key enzyme in folate metabolism
that catalyses the irreversible conversion of 5,10-methylenetetra-
hydrofolate to 5-methyltetrahydrofolate, which is the primary
circulating form of folate. This reaction is essential for both purine
nucleotide biosynthesis and remethylation of homocysteine to
methionine used in DNA methylation (Kim, 1999; Choi and
Mason, 2002). Two functional SNPs in the MTHFR gene, 677 C4T
(rs1801133) and 1298A4C (rs1801131), both associated with
reduced enzyme activity in vitro have been described. The MTHFR
677TT (homozygote) genotype results in 30% enzyme activity
in vitro compared with the CC wild-type, whereas the MTHFR 1298
CC genotype has been found to result in 60% enzyme activity
in vitro compared with the AA wild-type (Frosst et al, 1995;
Weisberg et al, 1998; Weisberg et al, 2001). Reduction of the
MTHFR enzyme activity may result in cancer risk increase through
impaired DNA repair synthesis and disruption of DNA methyla-
tion. In addition, it has been suggested that breast carcinogenesis
could be associated with alteration of oestrogen receptor gene
methylation patterns (Nass et al, 2000) and global DNA methyla-
tion (Soares et al, 1999). The association of MTHFR 677 C4T and
1298 A4C polymorphisms with breast cancer risk have been
investigated and results of meta-analyses have shown a statistically
significant association of the MTHFR 677 C4T polymorphism
with breast cancer risk (Macis et al, 2007; Zhang et al, 2010; Qi
et al, 2010).
Recently, the PHB 1630 C4T SNP was shown to be associated
with a twofold increased breast cancer risk in Polish BRCA1
mutation carriers of the CT, TT and combined CTþTT genotypes
(Jakubowska et al, 2007a). Similarly the MTHFR 677C4T SNP was
associated with a two to threefold increased risk of breast and
ovarian cancer in the same population (Jakubowska et al, 2007b).
In the current study we have evaluated both associations in a
large series of BRCA1 and BRCA2 mutation carriers from the
Consortium of Investigators of Modifiers of BRCA1 and BRCA2
(CIMBA) (Chenevix-Trench et al, 2007).
MATERIALS AND METHODS
Patients
Eligible study subjects were women who carried a deleterious germ
line mutation in BRCA1 or BRCA2 and were 18 years old or older.
Information on study subjects was submitted by centres partici-
pating in CIMBA. Details of the CIMBA initiative, information
about the participating centres and detailed inclusion criteria for
subjects can be found elsewhere (Chenevix-Trench et al, 2007).
Briefly, collected data included year of birth, mutation description,
family membership, ethnicity, country of residence, age at last
follow-up, ages at breast and ovarian cancer diagnosis, and
information on bilateral prophylactic mastectomy and prophylactic
oophorectomy. Related individuals were identified through a
unique family identifier. Only carriers of pathogenic mutations
were included in the study. These were mutations generating a
premature termination codon (frameshifts, small deletions and
insertions, nonsense mutations, splice site mutations and large
genomic rearrangements), large in-frame deletions that span one
or more exons, deletions of transcription regulatory regions
(promoter and/or first exons) expected to cause lack of expression
of mutant allele and missense variants classified as pathogenic by
Breast Cancer Information Core (BIC) or using the algorithms of
Goldgar et al (2004) and Chenevix-Trench et al (2007). Truncating
variants in exon 27 of BRCA2 were excluded.
All analyses were restricted to mutation carriers of self-
reported white European ancestry. A total of 4108 BRCA1 mutation
carriers, 2093 BRCA2 mutation carriers derived from 13 centres
participating in CIMBA were included in the analysis of rs6917 in
PHB gene, and 7056 BRCA1 mutation carriers and 3341 BRCA2
mutation carriers from 23 centres in that of rs1801133 in MTHFR
gene. The analysis included both related and unrelated mutation
carriers in order to maximise the number of samples in the
analysis.
All carriers participated in clinical or research studies at the host
institutions under ethically approved protocols and data were
analysed anonymously.
Genotyping
Genotypes for the two polymorphisms rs6917 in PHB and
rs1801133 in MTHFR were determined for each sample using
PCR-RFLP (Jakubowska et al, 2007a, b), Taqman or iPLEX
analyses (Table 1). The CIMBA genotyping quality control criteria,
described in detail in http://www.srl.cam.ac.uk/consortia/cimba/
eligibility/eligibility.html, were applied. Based on these criteria one
study (169 carriers) was excluded due to low concordance rate for
rs1801133, and 6 BRCA1 carriers for rs6917 were excluded because
of low number.
As an additional genotyping quality control assessment Hardy–
Weinberg equilibrium (HWE) was evaluated in unrelated subjects
for each polymorphism. There was no significant evidence of
deviation from HWE except for one study (1115 carriers) for
rs1801133 (HWE P-value¼ 8 10-6), so this was also excluded
from the analysis. After all exclusions the rs6917 in PHB gene was
analysed in 4102 BRCA1 and 2093 BRCA2 mutation carriers, and
the rs1801133 in MTHFR gene in 6211 BRCA1 and 2902 BRCA2
mutation carriers (Table 1).
Statistical analysis
The aim of the analysis was to evaluate the associations between
the two polymorphisms and the risk of breast or ovarian cancer for
BRCA1 and BRCA2 mutation carriers. For this purpose women
were classified according to their age of cancer diagnosis or their
age at last observation. Data were analysed within a retrospective
likelihood framework by modelling the likelihood of the observed
genotypes conditional on the disease phenotypes. This approach,
described in detail elsewhere (Antoniou et al, 2007), adjusts for the
fact that BRCA1 and BRCA2 mutation carriers were not randomly
sampled with respect to their phenotype. Two types of analyses
were carried out for each polymorphism. For the primary analysis,
the associations with breast and ovarian cancer were evaluated
separately for each disease. For the breast cancer risk association
analysis, mutation carriers were censored at the age of the first
breast cancer diagnosis, ovarian cancer diagnosis, bilateral
PHB and MTHFR polymorphisms and cancer risk in BRCA1/2 carriers
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prophylactic mastectomy or the age at last observation. For this
analysis, only mutation carriers censored at breast cancer were
considered as affected. To evaluate the associations with ovarian
cancer risk, carriers were censored at the age of ovarian cancer
diagnosis, bilateral prophylactic oophorectomy or age at last
observation, whichever occurred first. Only women censored at
ovarian cancer diagnosis were considered as affected in this
analysis. To allow for the fact that mutation carriers are at
risk of developing both breast and ovarian cancer, in a second
analysis we evaluated the associations between the SNPs
with both breast and ovarian cancer simultaneously using a
competing risk analysis, by estimating simultaneously HRs for
both breast and ovarian cancers. Details of this method have been
described elsewhere (Antoniou et al, 2010; Ramus et al, 2011;
Barnes et al, 2012). A different censoring process was used in
this case, whereby individuals were followed up to the age of
the first breast or ovarian cancer diagnosis, and were considered
to have developed the corresponding disease. No follow-up was
considered after the first cancer diagnosis. Individuals were
censored for breast cancer at the age of bilateral prophylactic
mastectomy and for ovarian cancer at the age of bilateral
oophorectomy, and were assumed to be unaffected for the
corresponding disease. The remaining individuals were censored
at the age at last observation and were assumed to be unaffected
for both diseases.
All analyses were stratified by study group and country of
residence, and used calendar-year and cohort-specific cancer
incidences for BRCA1 and BRCA2 (Antoniou et al, 2008). A robust
variance-estimation approach was used to allow for the non-
independence among related carriers (Boos, 1992).
RESULTS AND DISCUSSION
In this study, a total of 6195 individuals including 4102 BRCA1 and
2093 BRCA2 mutation carriers from 11 countries were eligible for
inclusion in the analysis of the PHB 1630 C4T (rs6917)
polymorphism (Table 1). The main analysis included all available
mutation carriers, including the Polish BRCA1 mutation carriers
used in the previous reports (Jakubowska et al, 2007a; Jakubowska
et al, 2007b). There was no evidence of an association of rs6917
with breast or ovarian cancer risk for mutation carriers when the
risks were evaluated separately (Table 2). However, the competing
risk analysis, where associations were evaluated simultaneously for
breast and ovarian cancer provided some evidence of association
between the rare homozygote TT genotype with both breast cancer
risk (HR 1.50, 95%CI 1.10–2.04) and ovarian cancer risk (HR 2.16,
95%CI 1.24–3.76) for BRCA1 mutation carriers (Table 3). The
breast and ovarian cancer HRs for the TT genotype in
the competing risk analysis were in the same direction as the
Table 1 Number of BRCA1 and BRCA2 carriers by study group and genotyping platforms
Study Countrya
BRCA1,
N
BRCA2,
N
Genotyping
Platform
PHB 1630 C4T
Epidemiological study of BRCA1 & BRCA2 mutation carriers (EMBRACE) UK and Eire 823 651 iPLEX
Fox Chase Cancer Centre (FCCC) USA 78 51 iPLEX
Georgetown University USA 32 15
Hereditary Breast and Ovarian study Netherlands (HEBON) The Netherlands 760 285 iPLEX
Helsinki Breast Cancer Study (HEBCS) Finland 103 104 iPLEX
International Hereditary Cancer Centre (IHCC) Poland 696 0 PCR-RFLP
Iceland Landspitali - University Hospital (ILUH) Iceland 0 86 iPLEX
Interdisciplinary Health Research International Team Breast Cancer Susceptibility (INHERIT BRCAs) Quebec -Canada 73 82 Taqman
kConFab Australia 519 415 iPLEX
Mayo Clinic (MAYO) USA 214 115 iPLEX
Pisa Breast Cancer Study (PBCS) Italy 76 41 iPLEX
Swedish Breast Cancer Study (SWE-BRCA) Sweden 468 127 iPLEX
University of Pennsylvania (UPENN) USA 260 121 iPLEX
Total 4102 2093
MTHFR677 C4T
Spanish National Cancer Centre (CNIO) Spain, Greece 168 202 Taqman
Deutsches Krebsforschungszentrum (DKFZ) Germany 68 29 Taqman
Epidemiological study of BRCA1 & BRCA2 mutation carriers (EMBRACE) UK and Eire 642 469 iPlex
Fox Chase Cancer Centre (FCCC) USA 80 54 iPlex
German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) Germany 559 283 Taqman
Genetic modifiers of cancer risk in BRCA1/2 mutation carriers (GEMO) France, USA 1075 536 iPlex
Hereditary Breast and Ovarian study Netherlands (HEBON) The Netherlands 480 0 iPlex
Helsinki Breast Cancer Study (HEBCS) Finland 101 103 iPlex
International Hereditary Cancer Centre (IHCC) Poland 686 0 PCR-RFLP
Interdisciplinary Health Research International Team Breast Cancer Susceptibility (INHERIT BRCAs) Quebec -Canada 72 82 Taqman
kConFab Australia 409 322 iPlex
Mayo Clinic (MAYO) USA 106 56 iPlex
Milan Breast Cancer Study Group (MBCSG) Italy 246 132 Taqman
Modifier Study of Quantitative Effects on Disease (ModSQuaD) Czech Republic, Belgium 132 35 Taqman
National Cancer Institute (NCI) USA 139 57 Taqman
National Israeli Cancer Control Center (NICCC) Israel 221 129 Taqman
Ontario Cancer Genetics Network (OCGN) Canada 180 130 Taqman
Odense University Hospital (OUH) Denmark 109 0 Taqman
Pisa Breast Cancer Study (PBCS) Italy 56 32 Taqman
Swedish Breast Cancer Study (SWE-BRCA) Sweden 427 130 Taqman
University of Pennsylvania (UPENN) USA 255 121 Taqman
Total 6211 2902
Abbreviations: MTHFR, methylene-tetrahydrofolate reductase; PHB, prohibitin; RFLP, restriction fragment length polymorphism. aCountry of the clinic at which carriers are
recruited
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corresponding breast and ovarian cancer HR estimates in the
analysis in which the breast and ovarian cancer associations were
assessed separately (Table 2). The analyses that investigated the
breast and ovarian cancer risk associations separately yielded no
evidence of association with the TT genotype. When evaluating the
associations with a single disease (breast or ovarian) in the
primary analysis, individuals who developed the other disease were
assumed to be unaffected in the analysis (i.e. treated as ‘controls’).
Under this analysis, a potential bias could arise if PHB 1630 C4T
is associated with both breast and ovarian cancer: if the magnitude
of the true breast and ovarian cancer relative risks conferred by
PHB 1630 C4T are in the same direction, then such an analysis
could lead to an attenuation of the estimated associations (Barnes
et al, 2012). Therefore, a plausible explanation for the apparent
discrepancy between the two analyses could be due to this source
of bias. However, the number of BRCA1 mutation carriers with the
PHB 1630 TT genotype is limited and larger studies will be
required to clarify this. The association with the TT genotype
remained significant after excluding the Polish samples from the
previously published study (Table 3).
A total of 6211 BRCA1 and 2902 BRCA2 participants from 16
countries were assessed for the associations between the common
polymorphism 677C4T in MTHFR (rs1801133) and breast or
ovarian cancer risk for women who harboured a germline
mutation in either BRCA1 or BRCA2 (Table 1). When breast and
ovarian cancer associations were evaluated separately (Table 4)
or simultaneously (competing risk analysis) (Table 3), there
was no evidence of association between the polymorphism with
either disease for BRCA1 or BRCA2 mutation carriers. This
observation is in contrast to previous findings in smaller studies
of BRCA1 mutation carriers (Gershoni-Baruch et al, 2000; Pepe
et al, 2007).
Table 2 PHB 1630 C4T genotype frequencies by (a) disease status and
breast cancer hazard ratio estimates; (b) disease status and ovarian cancer
hazard ratio estimates
Gene Genotype
Unaffected
n (%)
Affected
n (%) HR 95% CI P-value
(a)a
BRCA1 CC 1443 (69.7) 1388 (68.3) 1.00
CT 575 (27.8) 574 (28.3) 1.04 0.92–1.18
TT 52 (2.5) 70 (3.4) 1.35 0.99–1.84
2df test 0.17
Per-Allele 1.08 0.97–1.21 0.15
BRCA2 CC 672 (67.9) 714 (64.7) 1.00
CT 293 (29.9) 354 (32.1) 1.15 0.96–1.37
TT 25 (2.5) 35 (3.2) 1.13 0.70–1.82
2df test 0.29
Per-Allele 1.12 0.96–1.30 0.14
(b)b
BRCA1 CC 2368 (68.9) 463 (69.6) 1.00
CT 972 (28.3) 177 (26.6) 0.93 0.83–1.06
TT 97 (2.8) 25 (3.8) 1.49 0.91–2.45
2df test 0.18
Per-Allele 1.03 0.87–1.23 0.73
BRCA2 CC 1274 (66.0) 112 (68.3) 1.00
CT 603 (31.3) 44 (26.8) 0.80 0.55–1.15
TT 52 (2.7) 8 (4.9) 1.63 0.67–3.99
2df test 0.21
Per-Allele 0.96 0.67–1.38 0.84
Abbreviation: PHB, prohibitin. aDiagnosed with breast cancer. bDiagnosed with
ovarian cancer.
Table 3: PHB 1630 C4T and MTHFR 677 C4T genotype frequencies by disease status, BRCA1/2 mutation and, breast and ovarian cancer hazard ratio
estimates in competing risk analysis
Unaffected n (%) Ovarian cancer n (%) HR 95% CI P-value Breast cancer n (%) HR 95% CI P-value
PHB 1630 C4T
BRCA1
CC 1155 (69.8) 334 (69.2) 1.00 1342 (68.3) 1.00
CT 465 (28.1) 130 (26.9) 0.99 0.78-1.25 554 (28.2) 1.04 0.92-1.19
TT 34 (2.1) 19 (3.9) 2.16 1.24–3.76 69 (3.5) 1.50 1.10–2.04
Per-allele 1.16 0.93–1.41 0.19 1.11 0.99–1.23 0.06
BRCA1 excluding IHCC
CC 933 (67.9) 233 (65.8) 1.00 1136 (67.7) 1.00
CT 412 (30.0) 103 (29.1) 0.98 0.75–1.29 478 (28.5) 0.99 0.86–1.14
TT 29 (2.1) 18 (5.1) 2.32 1.34–4.05 64 (3.8) 1.43 1.05–1.98
Per-allele 1.18 0.94–1.48 0.15 1.07 0.95–1.20 0.27
BRCA2
CC 616 (67.1) 83 (71.6) 1.00 687 (64.9) 1.00
CT 282 (30.7) 28 (24.1) 0.69 0.45–1.07 337 (31.8) 1.08 0.90–1.30
TT 20 (2.2) 5 (4.3) 1.46 0.44–4.81 35 (3.3) 1.24 0.81–1.89
Per-Allele 0.86 0.53–1.39 0.54 1.09 0.94–1.27 0.23
MTHFR 677 C4T
BRCA1
CC 976 (43.3) 349 (43.1) 1.00 1344 (42.7) 1.00
CT 1000 (44.4) 361 (44.6) 0.95 0.79–1.13 1425 (45.3) 0.99 0.89–1.09
TT 279 (12.4) 99 (12.2) 0.93 0.72–1.21 378 (12.0) 0.96 0.82–1.13
Per-allele 0.96 0.85–1.08 0.51 0.98 0.99–1.06 0.63
BRCA2
CC 471 (43.0) 74 (42.1) 1.00 688 (42.2) 1.00
CT 481 (43.9) 85 (48.3) 1.09 0.76–1.57 741 (45.4) 1.05 0.90–1.23
TT 143 (13.1) 17 (9.7) 0.74 0.41–1.34 202 (12.4) 0.95 0.76–1.20
Per-allele 0.93 0.72–1.20 0.57 1.00 0.90–1.11 0.98
Abbreviations: MTHFR, methylene-tetrahydrofolate reductase; PHB, prohibitin. Significant results are marked in bold.
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In this multicentre study we were unable to confirm the
modifying effect of the MTHFR 677C4T polymorphism on breast
cancer risk for BRCA1 carriers. We also did not detect an
association of the above polymorphism with breast and/or ovarian
cancer risk for BRCA2 mutation carriers. Previous studies were
restricted to specific populations, and may potentially repre-
sent population specific effects (Gershoni-Baruch et al, 2000;
Jakubowska et al, 2007b; Pepe et al, 2007; Beetstra et al, 2008).
This explanation is confirmed by the fact that the frequency of
677TT genotype was substantially different between studies: 8.5%
(52 in 609 carriers) in the Polish study (Jakubowska et al, 2007b),
13.5% (5 in 37 carriers) in a small study from Australia (Beetstra
et al, 2008), 17% (82 in 484 carriers) in an Italian study (Pepe et al,
2007) and 21% (43 in 205 carriers) among Jewish carriers
(Gershoni-Baruch et al, 2000). It is also noticeable that in Polish
and Jewish carriers the modifying effect of MTHFR 677C4T
polymorphism was observed for 677T homozygotes, whereas in the
Italian study an increased risk of breast cancer was detected in
carriers of the 677T allele. The genotype frequency of MTHFR
677CTT in this multi-population study was 12.2% with an equal
distribution in breast cancer patients, ovarian cancer patients
and unaffected individuals (12.1, 12.8 and 12.2, respectively).
However, the most likely explanation could be the fact that all
previous studies were based on much smaller data sets and
associations based on those studies could represent false-positive
findings. Although the present analysis has been performed in a
much larger sample set of mutation carriers and therefore has a
greater power to detect an association compared with any
previously published studies it remains underpowered to identify
weaker effects.
In conclusion, these findings show that in general the MTHFR
677C4T polymorphism is not likely to have an important role as
modifier of breast and/or ovarian cancer risks in BRCA1/2
mutation carriers. There was some evidence that the PHB 1630
C4T polymorphism is associated with breast and ovarian cancer
risks in BRCA1 mutation carriers in the competing risk analysis,
but this would need to be evaluated in additional analyses with
larger number of mutation carriers. Future analyses should also
aim to assess the associations with other clinical and tumour
characteristics.
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Abbreviation: MTHFR, methylene-tetrahydrofolate reductase. aDiagnosed with breast
cancer. bDiagnosed with ovarian cancer.
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